Haploidentical Bone Marrow Transplantation with Posttransplant Cyclophosphamide As a Curative Alternative to Matched Sibling Donor Transplantation in Pediatric Patients with Severe Aplastic Anemia | Synapse
March 3, 2026
Haploidentical Bone Marrow Transplantation with Posttransplant Cyclophosphamide As a Curative Alternative to Matched Sibling Donor Transplantation in Pediatric Patients with Severe Aplastic Anemia
Key Points
Haploidentical transplantation with posttransplant cyclophosphamide shows improved outcomes.
In a cohort of pediatric patients, survival rates reflect competitive success against matched sibling donor transplants.
Assessment of performance utilized clinical outcomes from patient records and treatment responses.
This approach emphasizes the need for wider acceptance of alternative donor strategies in pediatric cases.